phentolamine has been researched along with Diabetes Mellitus, Type 2 in 9 studies
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.
phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We measured forearm mean blood flow (MBF) and mean vascular conductance (MVC) responses to isocapnic hypoxia in seven healthy and eight type 2 diabetic subjects during local intra-arterial saline infusion and alpha-adrenergic blockade (phentolamine)." | 3.72 | Vasomotor responses to hypoxia in type 2 diabetes. ( Best, M; Eastwood, PR; Green, DJ; Halliwill, JR; O'Driscoll, G; Walsh, JH; Weisbrod, CJ, 2004) |
| "NO inhibition and type 2 diabetes abolished this correlation." | 1.34 | Impact of type 2 diabetes on nitric oxide and adrenergic modulation of myocardial perfusion. ( Buus, NH; Bøtker, HE; Bøttcher, M; Madsen, MM; Nielsen, TT; Schmitz, O; Søndergaard, HM, 2007) |
| "In summary, in type 2 diabetes compared with control subjects, (1) the vasoconstriction response to intraarterial NE is greater, (2) plasma NE and NE2 are similar, suggesting similar levels of systemic SNSa, and (3) arterial alpha-adrenergic tone is greater." | 1.30 | Heightened norepinephrine-mediated vasoconstriction in type 2 diabetes. ( Galecki, AT; Halter, JB; Hogikyan, RV; Supiano, MA, 1999) |
| "When mannoheptulose was introduced 15 min after starting perfusion with 27 mM glucose, inhibition was apparent in non-diabetic rats, but not in STZ." | 1.27 | B cell insensitivity in a rat model of non-insulin-dependent diabetes. Evidence for a rapidly reversible effect of previous hyperglycemia. ( Grill, V; Ostenson, CG; Westberg, M, 1987) |
| "Diabetic microangiopathy is regarded as the most important pathogenic factor." | 1.27 | [Disorders of erectile potency in diabetes mellitus]. ( Floth, A; Holzmann, RM; Schramek, P, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gurkan, S | 1 |
| Gur, O | 1 |
| Gur, DO | 1 |
| Gocmez, SS | 1 |
| Ege, T | 1 |
| Weisbrod, CJ | 1 |
| Eastwood, PR | 1 |
| O'Driscoll, G | 1 |
| Walsh, JH | 1 |
| Best, M | 1 |
| Halliwill, JR | 1 |
| Green, DJ | 1 |
| Madsen, MM | 1 |
| Søndergaard, HM | 1 |
| Bøttcher, M | 1 |
| Buus, NH | 1 |
| Schmitz, O | 1 |
| Bøtker, HE | 1 |
| Nielsen, TT | 1 |
| Hogikyan, RV | 1 |
| Galecki, AT | 1 |
| Halter, JB | 1 |
| Supiano, MA | 1 |
| Grill, V | 1 |
| Westberg, M | 1 |
| Ostenson, CG | 1 |
| Broadstone, VL | 1 |
| Pfeifer, MA | 1 |
| Bajaj, V | 1 |
| Stagner, JI | 1 |
| Samols, E | 1 |
| Schramek, P | 1 |
| Holzmann, RM | 1 |
| Floth, A | 1 |
| Krotkiewski, M | 1 |
| Górski, J | 1 |
| Giugliano, D | 1 |
| Di Pinto, P | 1 |
| Ceriello, A | 1 |
| Saccomanno, F | 1 |
| Passariello, N | 1 |
| D'Onofrio, F | 1 |
9 other studies available for phentolamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Vasodilation Responses to Non-Selective α-Adrenergic Blockage of Coronary Bypass Grafts in Diabetic and Non-Diabetic Patients: In Vitro Study.
Topics: Adrenergic alpha-Antagonists; Aged; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Dose-Response | 2015 |
Vasomotor responses to hypoxia in type 2 diabetes.
Topics: Adrenergic alpha-Antagonists; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Female | 2004 |
Impact of type 2 diabetes on nitric oxide and adrenergic modulation of myocardial perfusion.
Topics: Adenosine; Adrenergic alpha-Antagonists; Blood Pressure; Coronary Circulation; Diabetes Mellitus, Ty | 2007 |
Heightened norepinephrine-mediated vasoconstriction in type 2 diabetes.
Topics: Adrenergic alpha-Antagonists; Diabetes Mellitus, Type 2; Epinephrine; Female; Forearm; Glucose Toler | 1999 |
B cell insensitivity in a rat model of non-insulin-dependent diabetes. Evidence for a rapidly reversible effect of previous hyperglycemia.
Topics: 1-Methyl-3-isobutylxanthine; Animals; B-Lymphocytes; Diabetes Mellitus, Experimental; Diabetes Melli | 1987 |
Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Adult; Arginine; Blood Glucose; Catecholamines; Diabetes Mellitus, Typ | 1987 |
[Disorders of erectile potency in diabetes mellitus].
Topics: Aged; Alprostadil; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 1988 |
Effect of muscular exercise on plasma C-peptide and insulin in obese non-diabetics and diabetics, type II.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Mid | 1986 |
Impaired insulin secretion in human diabetes mellitus. Interactions between naloxone, phentolamine and lysine acetylsalicylate upon glucose induced insulin release.
Topics: Adult; Analgesics; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Hu | 1985 |